BioCentury | Sep 1, 2017
Company News

Medivir grants Ascletis rights to preclinical HCV candidate

Medivir AB (SSE:MVIR B) granted Ascletis BioScience Co. Ltd. (Hangzhou, China) exclusive development and commercialization rights in Greater China to preclinical HCV candidate MIV-802 . Medivir received an upfront payment and is eligible for milestones and...
BioCentury | Aug 18, 2017
Company News

Ascletis gains preclinical HCV candidate

Medivir AB (SSE:MVIR B) granted Ascletis BioScience Co. Ltd. (Hangzhou, China) exclusive development and commercialization rights in Greater China to preclinical HCV candidate MIV-802 . Medivir received an upfront payment and is eligible for milestones and...
BioCentury | Feb 8, 2017
Distillery Therapeutics

Neurology

INDICATION: Pain In vitro and mouse studies identified an acrylic acid-based agonist of the TREK-1 potassium channel that could help treat pain. Chemical synthesis of analogs of a dihydroxyphenylacrylic acid and testing in HEK cells...
BioCentury | Oct 3, 2016
Clinical News

Faldaprevir: Interim Phase IIa data

Interim data from 11 treatment-naive, non-cirrhotic patients with chronic HCV genotype 4 infection in an open-label, U.S. Phase IIa trial showed that once-daily 60 and 120 mg TD-6450 plus once-daily 120 mg oral faldaprevir and...
BioCentury | Oct 3, 2016
Clinical News

TD-6450: Interim Phase IIa data

Interim data from 11 treatment-naive, non-cirrhotic patients with chronic HCV genotype 4 infection in an open-label, U.S. Phase IIa trial showed that once-daily 60 and 120 mg TD-6450 plus once-daily 120 mg oral faldaprevir and...
BioCentury | Aug 22, 2016
Company News

Medivir, Trek Therapeutics deal

Medivir granted Trek exclusive, worldwide rights outside of Taiwan and China, including Hong Kong and Macau, to develop and commercialize MIV-802 . The pan-genotypic uridine nucleotide HCV NS5B polymerase inhibitor is in preclinical testing. Medivir is...
BioCentury | Aug 1, 2016
Company News

Vertex, Trek Therapeutics deal

Vertex granted Trek exclusive, worldwide rights to develop and commercialize lomibuvir ( VX-222 ) and merimepodib ( VX-497 ) to treat infectious disease. Vertex is eligible for undisclosed milestones and royalties. Lomibuvir, a non-nucleoside HCV NS5B polymerase inhibitor, and...
BioCentury | Jul 18, 2016
Clinical News

Faldaprevir: Phase IIa started

Trek began an open-label, international Phase IIa trial to evaluate once-daily 120 mg oral TD-6450 plus 120 mg oral faldaprevir with and without ribavirin for 12 weeks in 25 patients. Trek has exclusive, worldwide rights...
BioCentury | Jul 18, 2016
Clinical News

TD-6450: Phase IIa started

Trek began an open-label, international Phase IIa trial to evaluate once-daily 120 mg oral TD-6450 plus 120 mg oral faldaprevir ( BI 201335 ) with and without ribavirin for 12 weeks in 25 patients. Trek has exclusive,...
BioCentury | Nov 23, 2015
Clinical News

Faldaprevir: Phase IIa started

Trek began a double-blind, U.S. Phase IIa trial to evaluate 60 and 120 mg TD-6450 once daily with 120 mg oral faldaprevir once daily and ribavirin twice daily for 12 weeks in about 24 treatment-naive...
Items per page:
1 - 10 of 33